MAGRAL 160

About MAGRAL 160

MAGRAL 160 is a pharmaceutical formulation containing the active ingredientmegestrol acetate 160 mg, a synthetic progestin known for its multifaceted therapeutic benefits. This medication is widely recognized for its role in managing conditions associated with severe weight loss and appetite suppression. The primary action of MAGRAL 160 revolves around improving appetite and promoting weight gain, especially in patients suffering from anorexia, cachexia, or unexplained serious weight loss. Additionally,megestrol acetateacts as an antineoplastic agent, making it effective in treating specific types of hormone-dependent malignancies, such as breast and endometrial cancers. Its ability to stimulate appetite and slow wasting syndromes marks a critical intervention for patients with chronic illnesses and cancer-related anorexia.

What is MAGRAL 160?

MAGRAL 160 is an oral medication whose active component,megestrol acetate 160 mg, functions primarily as a progestin hormone. Progestins mimic the natural hormone progesterone and influence hormone-responsive tissues. MAGRAL 160 is utilized both for its hormonal effects, to combat certain cancers, and for its appetite-stimulating properties, helping patients regain lost weight and improve nutritional status. It is administered by prescription and taken orally, with dosages tailored according to the condition being treated and the patients response.

Uses of MAGRAL 160

• To treatanorexia(loss of appetite) andcachexia(wasting syndrome), especially in patients experiencing serious unexplained weight loss.

• To manage weight loss in chronic conditions such as cancer or HIV/AIDS.

• As anantineoplastic agentin treating hormone-dependent cancers, particularlybreast cancerandendometrial cancer.

• To improve overall nutritional status in patients debilitated by chronic illness or cancer therapy.

• In certain cases, used off-label for other hormone-related disorders or symptoms such as menopausal hot flashes, though this is less common.

Side Effects of MAGRAL 160

• Weight gain (primarily through increased appetite)

• Nausea and vomiting

• Fluid retention or edema (swelling of limbs)

• Vaginal bleeding or spotting

• Changes in sexual function, including decreased libido or impotence

• Headache and dizziness

• Gastrointestinal distress such as constipation or diarrhea

• Fatigue, weakness, or insomnia

• Potential risk of blood clots or thromboembolism symptoms (e.g., limb pain, chest pain, shortness of breath)

• Long-term use may lead to hormonal imbalances affecting bone density, glucose metabolism, and cardiovascular health

Patients should report any unusual symptoms promptly and undergo regular medical monitoring to mitigate risks.